Laval, Canada-based Valeant Pharmaceuticals CEO Joe Papa said the company is focusing on increasing its revenue and paying down debt at the New York City-based RBC investor conference, Reuters reports.
1. Valeant started the year by selling off $2.1 billion in assets.
2. The company has $30.4 billion in lingering debt. Through selling off strategic assets, however, it avoided paying additional interest on a bond.
3. As of Feb. 24, 2017, Valeant shares were trading at $16.24 per share. The company has a 52-week high of $86.50 and a 52-week low of $13.